Ladies and gentlemen thank you for standing by and welcome to the Q2 2014 Concord Medical Services Holdings Limited Earnings Call. At this time, all participants are in a listen-only mode. There will be a presentation followed by a question-and-answer session. (Operator Instructions). I must advise you that this conference is being recorded today, 14 of August, 2014. I would now like to hand the conference over to your speaker for today, Mr. Bill Zima. Please go ahead sir.

Hello everyone and welcome to Concord Medical's second quarter 2014 earnings conference call. Concord Medical's earnings release was distributed earlier and you can find a copy on the company's website as well as on newswire services. Today you will hear from Dr. Jianyu Yang, Concord Medical’s Chairman and Chief Executive Officer; and Mr. Adam Sun, Chief Investment Officer. After their prepared remarks, Dr. Yang and Mr. Sun will be available to answer your questions. Mr. Kong Yap Concord's new Chief Financial Officer is also on the call today. Before we continue, please note that the discussion today will contain forward-looking statements made under the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 and within the meaning of Section 21E of the Securities Exchange Act of 1934 as amended. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from our current expectations. Potential risks and uncertainties include but are not limited to those outlined in our public filings with the SEC. Concord Medical does not undertake any obligation to update any forward-looking statement except as required under applicable law. Both the company's earnings release and remarks made during this call include discussions of certain unaudited non-GAAP financial measures. Our earnings release contains a reconciliation of the unaudited non-GAAP measures to the most directly comparable unaudited GAAP measures. As a reminder, this conference call is being recorded. In addition, a webcast of this conference call will also be available on Concord Medical’s website. With that said, I would now like to turn the call over to Concord Medical’s Chairman and CEO. Dr. Yang. Please go ahead.

[Foreign Language]. Hello everyone. Welcome to Concord Medical’s 2014 second quarter earnings conference call. [Foreign Language]. Our second quarter results demonstrate how we continued the stable growth in our business since the beginning of the year. Total revenue generated from the network business grew to RMB161 million or $25.9 million, representing a 10.4% increase year-over-year our higher pricing centers such as PET-CT centers and Cyber Knife centers are increasingly becoming major growth drivers to total revenue. This success is a result of rising patient awareness and the willingness to pay for higher level services and treatment. In the second quarter, PET-CT centers accounted for 7% of the network business growth and our Cyber Knife centers accounted for 15%. Importantly, overall management cost control for this segment of our business has improved significantly as our SG&A expenses as a percent of total revenue has fallen to 16% this quarter from 22% in the same period last year. [Foreign Language]. Shifting to our hospital section, in the second quarter Chang’an Hospital performance has also increased significantly with revenue increasing to RMB124.5 million or $20.1 million, up 14.8% from same period last year and up 13.6% sequentially from the first quarter of this year. [Foreign Language]. Net income attributable to ordinary shareholders in the second quarter of 2014 was RMB35 million or $5.6 million, a 20.4% increase from the same period last year. Basic and diluted earnings per ADS increased to $0.13 from $0.11 last year. [Foreign Language] Given our strong performance this quarter, we’ll reiterate Concord with our full year guidance forecast of earnings in the range of US$0.45 to US$0.50 per ADS, or US$20.3 million to US$22.5 million in net income attributable to ordinary shareholders. [Foreign Language] Second quarter relates with progress in the design and construction for Concord Medical Hospitals.…

Thank you Dr. Yang and thank you [Jia Chin]. Good morning and good evening everyone. I am Kong Yap. First of all, I would like to thank you all for joining us today for our 2014 second quarter earnings release conference call. As Dr. Yang has mentioned we’re very pleased with our strong financial and operating performance. I also share the excitements for impressive operating revenue since the beginning of the year for our network business, hospital business, the constructions of our specialty cancer hospitals and the free-standing radiotherapy centers. I am very confident that our management continued to ride on this momentum to deliver the strong performance for the coming months and we are looking forward to sharing with you more updates of these business developments in the future. Thank you.

[Foreign Language]. At this point, I would like to turn the call over to Mr. Adam Sun to review our financial results for the second quarter of 2014.

Thank you, Dr. Yang. Hello everybody. We have issued the 2014 second quarter earnings release this morning. You can find the full release on our financial website as well as our IR website. As Dr. Yang said we are pleased with the quarterly results, following some financial highlights for the quarter. Total net revenue which consists of net revenues generated from the network business and hospital business and hospital business was RMB285.3 million or $46 million in the second quarter of 2014, a 12.3% increase from RMB254 million in the second quarter of 2013. Gross profit in the second quarter of 2014 was RMB110.1 million or $17.7 million a 4.7% increase from RMB95.2 million in the second quarter of 2013. Net income attributable to ordinary shareholders in the second quarter of 2014 was RMB35 million or $5.6 million a 20.4% increase from RMB29.1 million in the second quarter of 2013. Basic and diluted earnings per ADS in the second quarter were RMB0.78 or $0.13 compared with RMB0.65 in the second quarter of 2013. Adjusted EBITDA in the second quarter of 2014 was RMB122.1 million or $19.7 million, a 17.1% from RMB104.3 million in the second quarter of 2013. For this quarter our key financial metrics is as follows. The gross margin for the business in this quarter was 38.58% compared to 41.4% in the second quarter of 2013. A negative trend of 282 basis points, of which the gross margin for the network business was 57.2% compared to 59.7% in the same quarter of last year, a negative trend of 250 basis points, mainly due to higher compensation, consumable and depreciation expenses. The gross margin for the hospital business was 14.5% compared to 16.9% in the same quarter of last year, a negative trend of 240 basis points due to…

(Operator Instructions). Your first question comes from the line of Isabella Zhao from Morgan Stanley. Please go ahead.

[Foreign Language]. I will translate my question into English later. [Foreign Language]. I have two questions. The first question is regarding the operating expenses issue. I noticed that there is a big drop in this quarter and I'm wondering the reason behind and what we should look like in the second half of the year. And my next question is for Dr. Yang. And can you provide us a rough timeline for the construction and the starting of operation for Shanghai and the Beijing hospital and also I remember you mentioned also plan to get out all radiotherapy centers and can you me - can you give us more color on that? Thank you very much.

Alright Isabella, let me try to answer your questions first, and then I’ll hand it over to Dr. Yang. So, as for the operating expenses as Dr. Yang mentioned in his speech as a percentage of revenue we have seen a very big improvement of this quarter. The total operating expenses as a percentage of revenue was 16% compared to 22% over the same quarter last year and of which close to [selling] and the general and administrative expenses have seen improvements of around 300 basis points in both categories. I think the main reason there are two faults. On the one hand, we have initiated the cost control measures since last year and gradually as we streamlined our management system and strengthened cost control and make cost control measures key for our centers and all the major physicians it’s early, so we finally seen all these metrics taking effect. So that’s we’ve good improvements in general and administrative expenses, as we see both travel, entertainment and rental expenses showing improvements in this quarter. And secondly, in terms of our selling expenses, so we are seeing lower marketing and selling expenses, especially related to our telemedicine business, and as we’ve discussed in the previous quarters, we have invested very substantially into the new business units and currently we are in conducting an internal business review to determine the strategy for this unit and as the review is going to close we’ll be able to share the result of that review and also the new strategy for the telemedical business pretty soon with the investors. With that I would like to turn it over to Dr. Yang.

[Foreign Language] So in our strategy, we are planning to build three core cancer hospitals in Beijing, Shanghai and Guangzhou. [Foreign Language] In Beijing, we chose the Beijing International Medical Center as our dome to build our hospital and which is located in Tongzhou District. Right now, the whole franchise is still in the process of the pre-construction period, and when completed we will be prepared completely. [Foreign Language] In Hongqiao, we have acquired the land and still in the process of plaining land and in pre-preparation work. Now we are hiring the two famous design groups to work on this project. [Foreign Language] We expect that its construction period will be three years. [Foreign Language] The Shanghai project will be located in Shanghai New Hongqiao International Medical Center. [Foreign Language] So these hospital will be the only cancer specialized hospital in this [part of zone]. [Foreign Language] In this project, we’ve already made decision to choose the American architecture design firm and domestic local design firm. [Foreign Language] About the plan, medical planning and micro process will be provided by MD Anderson's completely. [Foreign Language] We expect to build a specialized the hospital in Shanghai which will be same as of our specialized hospital standards. [Foreign Language] The expected construction period of well be within three years. [Foreign Language] Another part is what you’ve said about the independent radiotherapy center. [Foreign Language] We are foreseeing to do some research at exploration point. [Foreign Language] When you take a lot long take of advantages to expand these projects with local resources. We are discussing several projects in the local area and next quarter we hope there is one product will be decided. Thank you Isabella. Next question please.

Our next question comes from the line of Sean Wu from JP Morgan. Please go ahead.

[Foreign Language] The first question is about the decision between building hospital on the [longhaul] like going out and buy some hospitals, obviously you wanted to like proton enter maybe you have to build something, otherwise, we need to make a more sense to buy hospitals and then convert in that technology knowhow. And number two a question about your decision to make dividend payout and could larger one recently, I know like you want to reward the investor. The thing about that you cannot look at investors two ways one is to buyback share, two if you are seeing the stock price keep in other way of course give people dividend and maybe we don't make dividend, because you have to pay tax. This of course is $0.30 per share, I think is also quite a bit of money and like now you carry probably a daily and cash and certainly investment in about $400 million, $500 million of long, short term debt, you are not exactly like cash rich if you are going to build three hospitals from (inaudible), I assume you will need a lot of cash. So why you think this is a prudent time to payout such amount of cash and how you can finance your hospital dividends in the future? Thank you.

[Foreign Language] Recently healthcare market in China is very hot. Many institutions is acquiring projects in China. And we are seeing this happening. [Foreign Language] (Inaudible) and the negotiator with the several projects and finally we decided to build our own. [Foreign Language] There are several reasons, first we are building cancer specialized hospital under the affordable target is very favorable for us. [Foreign Language] We want to build our own hospitals which will be having centralized international standards and but current hospitals in China their construction and all solutions are not qualified for us. [Foreign Language] There are huge gaps between American hospitals department setup and that in China. [Foreign Language]. That’s the reason why we from the very beginning, we are using the American architecture firms and design to build [hospitals] together. [Foreign Language]. Now in China healthcare reform system, direction -- China healthcare reform, the direction is very clear to encourage private customers into this market but the policy for public hospitals is not very clear and we are talking about this with our lawyers and the target is very certain for us. [Foreign Language]. So, it’s hard for us to combined hospitals different hospitals, different culture in our acquiring target in the future. [Foreign Language]. Because of we have very strong cash flow in our business, so by the Board of Directors, we hope that when we have strong cash flow, we will keep that return to our shareholders. [Foreign Language]. Although we are including our own cancer hospitals and we need cash but we are -- we will be focusing on oncology hospitals and we will trial back to gather cash for projects. [Foreign Language]. So, we will -- we expect to combine our cash flow with our not very high debt to satisfy our several projects. [Foreign Language]. Thank you, .

Thank you. Our next question comes from the line of [Peter Holzworth from Hanran Investments].

Hi gentlemen. Thank you for the call and also congratulations on the effective cost control. I have a question about the number of cases. It seems like there was flat growth year-on-year in the number of patient cases and also diagnostic cases as well. Could you talk a little bit about what contributed to that and also if you have a utilization rate on the diagnostic centers, I appreciate knowing that. And then I have a quick follow-up. Thank you.

Hi. And as you can see from our quarter earnings release, the case is treated within our network is basically flat, both in the treatment and diagnostic cases. First, it is an improvement over the same quarter -- over sequentially because I remember in the first quarter, you see that the treatment cases, there was a small decline. So this quarter, we’re seeing a flat growth. The reason for this is there is two-fold. On one hand, in terms of our treatment centers, the utilization rate is pretty high and some of our treatment centers even operating basically around the clock. So, there is a little room for increasing in terms of the number of treatment patients. So in the diagnostic centers, we are still seeing a growth of although smaller. And the reason for that is in this quarter we are focusing more upon the high paying cases, including PET-CT and which is showing very positive impact on both our revenue growth as well as our profitability. So, in terms of the diagnostic centers and their utilization rate, we haven’t done exact number, but my general impression is it is very high in the 60% to 70% average. And you said you have another follow-up question, [Peter].

Yes. Just on the [Shandong] hospital and the revenue streams, it looks like medicine revenue was the highest amount of revenue. And I was just wondering we’ve heard that part of the healthcare reform will eventually be the removal of pharmacies from hospitals, I was just wondering how if and when that does come, how would you handle it in this hospital and also your planned new hospitals? Thank you.

So first of all, for that hospital medicine attributed about 45% of the total revenue in the past quarter which is about the same from the previous two quarters and in fact it is lowest one. And yes you’re right, the government is implementing the policy to encourage hospitals, especially government hospitals to reduce their reliance on pharmaceutical sales. So they’ve set up very specific retails for the government hospitals, I think for a level-three hospitals percentage of revenue from medicine sales is kept I think 35% or 40% I don’t remember the exact number. So, into our hospital we are also trying very hard to improve the revenue mix, but it is very challenging task, the reason for that is number one China Hospital is a private hospital needs to compete in the market with the current hospitals, so it is a very competitive market as you can see. And secondly China Hospital it is the general hospital so we’ve been trying to implement a new strategy and focusing more upon cancer sales - I mean cancer patients, but it takes a very long time, a lot of work for us to implement that. So with that I think I believe that we’ll keep working on this issue and improving the revenue mix of our China Hospital but it is a long process. So in terms of our future hospitals, the revenue mix and as a percent of patients and also the targeting market will be totally different. So the hospitals we are planning in Beijing, Shanghai and Guangzhou as the CEO has mentioned will be a premium cancer specialty hospitals targeting the high network population as well as the commercial insurance population which will have totally different pay-ability and affordability for the treatment. So we in fact we will now dependent upon pharmacy (inaudible) sales in our premium hospitals but we will charge a market rate for the services of our doctors and also for the more high end and high quality treatment and services in our hospitals.

Thank you. And just a quick follow up, what would be the share of revenue from medicine in the new hospitals in Shanghai, Guangdong and Beijing? Thank you.

We are basically, we are not in our financial forecast, we are not focusing at all upon a mark to markup for the pharmaceutical sales. So our revenue or our profitability will cost I would say - close to 100% from the treatment and the services we charge for our -- to our patients.

Understand, very clear. Thank you very much and congratulations again.

Thank you.

Our last question will come from the line of [Huang Dai] from CICC. Please go ahead.

[Foreign Language] Let me translate my questions to English. I just want to ask a very simple question and that is, what the percentage of the network business is from the telemedicine and web business. And just may give more color those businesses such as the margins the gross and the future trends? Thank you.

[Foreign Language] The combination of healthcare IT is well remain a healthcare company is pursuing right now. [Foreign Language] Well this we built a specialized team and that we also accumulated three years of experience. [Foreign Language] We're going to combine our current network and network of have now based on treatment and to make a better analyzing network. [Foreign Language] Currently these treatments have not been calculated independently and we are pulling investments on it. [Foreign Language] Mainly serving for our account. [Foreign Language] In the future it is probably for us to extend -- expand these treatments outside of our group. [Foreign Language] From our account accumulation we want to serve more patients with these IT services. [Foreign Language] We will notify everybody in time. [Foreign Language] Thank you.

Okay. I have no further questions. Thank you.

All right. At this time, I now hand the call back to the management for final remarks.

Thank you for everyone. This concludes the presentation. You may now disconnect.